Introduction: The pharmaceutical industry is steadily moving away from daily oral medicines and toward advanced depot systems. This change is […]
Long Acting Injectable vs Oral Dosage Forms: Why Pharma is Shifting Toward Depot Systems Read More »
Introduction: A long acting injectable is only as strong as the attributes that define its performance. Critical Quality Attributes for
Introduction: Peptide Characterization for ANDA submission is a critical regulatory requirement to demonstrate that a generic peptide drug is equivalent
Peptide Characterization Requirements for ANDA Approval Read More »
Introduction: An Exenatide Sameness Study is a comprehensive analytical comparison conducted to demonstrate that a generic exenatide drug product is
Introduction: The Sameness Evaluation of Synthetic Peptides for ANDA is a critical regulatory requirement that ensures generic synthetic peptide drugs
Sameness Evaluation of Synthetic Peptides in ANDA: FDA Guidance Explained Read More »
Introduction: Navigating the Complexities of Extended-Release Parenterals The Challenges in Long Acting Injectable Formulation mainly involve creating drug systems that release medicine
Challenges in Long Acting Injectable Formulation Development and How to Overcome Them Read More »
Introduction: Orthogonal Analytical Techniques for ANDA Sameness Evaluation play a crucial role in demonstrating that a generic drug product is
Role of Orthogonal Analytical Techniques in ANDA Sameness Evaluation Read More »
Introduction: The Lanreotide Sameness Study is a comprehensive analytical exercise designed to prove that a generic lanreotide product is identical to the
Introduction: The Formulation Science Behind Long Acting Injectable Drug Delivery Technologies Long Acting Injectable Drug Delivery Technologies are changing how
Introduction: Analytical Strategies for Sameness Study are fundamental in demonstrating that a generic drug is equivalent to its Reference Listed
Analytical Strategies to Prove Sameness Between Generic and RLD Read More »
